BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28824055)

  • 1. Bronchodilator Effect of Tiotropium via Respimat
    Ogasawara T; Sakata J; Aoshima Y; Tanaka K; Yano T; Kasamatsu N
    Intern Med; 2017 Sep; 56(18):2401-2406. PubMed ID: 28824055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
    Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
    Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.
    Tashkin DP; Bateman ED; Jones P; Zubek VB; Metzdorf N; Liu D; Leonard T; Clerisme-Beaty E; Wise RA
    Respir Med; 2016 Nov; 120():91-100. PubMed ID: 27817821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
    Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
    BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
    Hodder R; Pavia D; Lee A; Bateman E
    Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
    Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.